Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

Denlinger CS, Sanft T, Baker KS, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Hudson M, Khakpour N, King A, Koura D, Lally RM, Langbaum TS, McDonough AL, Melisko M, Montoya JG, Mooney K, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Pirl W, Rodriguez MA, Ruddy KJ, Silverman P, Smith S, Syrjala KL, Tevaarwerk A, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA.

J Natl Compr Canc Netw. 2018 Oct;16(10):1216-1247. doi: 10.6004/jnccn.2018.0078.

PMID:
30323092
2.

Neoadjuvant twice daily chemoradiotherapy for esophageal cancer: Treatment-related mortality and long-term outcomes.

Samuels SE, Stenmark MH, Lee JY, McHugh JB, Hayman JA, Orringer MB, Urba SG, Sun L, Xie C, Kong FM, Cuneo KC.

Adv Radiat Oncol. 2017 May 25;2(3):308-315. doi: 10.1016/j.adro.2017.05.003. eCollection 2017 Jul-Sep.

3.

Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Denlinger CS, Sanft T, Baker KS, Baxi S, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Hudson M, Khakpour N, King A, Koura D, Kvale E, Lally RM, Langbaum TS, Melisko M, Montoya JG, Mooney K, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Rodriguez MA, Ruddy KJ, Silverman P, Smith S, Syrjala KL, Tevaarwerk A, Urba SG, Wakabayashi MT, Zee P, Freedman-Cass DA, McMillian NR.

J Natl Compr Canc Netw. 2017 Sep;15(9):1140-1163. doi: 10.6004/jnccn.2017.0146.

4.

NCCN Guidelines Insights: Palliative Care, Version 2.2017.

Dans M, Smith T, Back A, Baker JN, Bauman JR, Beck AC, Block S, Campbell T, Case AA, Dalal S, Edwards H, Fitch TR, Kapo J, Kutner JS, Kvale E, Miller C, Misra S, Mitchell W, Portman DG, Spiegel D, Sutton L, Szmuilowicz E, Temel J, Tickoo R, Urba SG, Weinstein E, Zachariah F, Bergman MA, Scavone JL.

J Natl Compr Canc Netw. 2017 Aug;15(8):989-997. doi: 10.6004/jnccn.2017.0132.

PMID:
28784860
5.

NCCN Guidelines Insights: Antiemesis, Version 2.2017.

Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, Brandt D, Dolan DE, Ellis G, Kim EJ, Kirkegaard S, Kloth DD, Lagman R, Lim D, Loprinzi C, Ma CX, Maurer V, Michaud LB, Nabell LM, Noonan K, Roeland E, Rugo HS, Schwartzberg LS, Scullion B, Timoney J, Todaro B, Urba SG, Shead DA, Hughes M.

J Natl Compr Canc Netw. 2017 Jul;15(7):883-893. doi: 10.6004/jnccn.2017.0117.

PMID:
28687576
6.

A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer.

LaBonte MJ, Yang D, Zhang W, Wilson PM, Nagarwala YM, Koch KM, Briner C, Kaneko T, Rha SY, Gladkov O, Urba SG, Sakaeva D, Pishvaian MJ, Hsieh RK, Lee WP, Lenz HJ.

Mol Cancer Ther. 2016 Sep;15(9):2251-8. doi: 10.1158/1535-7163.MCT-15-0908. Epub 2016 Jun 20.

7.

NCCN Guidelines Insights: Survivorship, Version 1.2016.

Denlinger CS, Ligibel JA, Are M, Baker KS, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Jones LW, King A, Ku GH, Kvale E, Langbaum TS, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Rodriguez MA, Ruddy KJ, Sanft T, Silverman P, Smith S, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA.

J Natl Compr Canc Netw. 2016 Jun;14(6):715-24.

8.

Palliative Care Version 1.2016.

Levy M, Smith T, Alvarez-Perez A, Back A, Baker JN, Beck AC, Block S, Dalal S, Dans M, Fitch TR, Kapo J, Kutner JS, Kvale E, Misra S, Mitchell W, Portman DG, Sauer TM, Spiegel D, Sutton L, Szmuilowicz E, Taylor RM, Temel J, Tickoo R, Urba SG, Weinstein E, Zachariah F, Bergman MA, Scavone JL.

J Natl Compr Canc Netw. 2016 Jan;14(1):82-113.

PMID:
26733557
9.

Survivorship: screening for cancer and treatment effects, version 2.2014.

Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Dizon D, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Raza M, Rodriguez MA, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA.

J Natl Compr Canc Netw. 2014 Nov;12(11):1526-31.

10.

Survivorship: nutrition and weight management, Version 2.2014. Clinical practice guidelines in oncology.

Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Dizon D, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Raza M, Rodriguez MA, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2014 Oct;12(10):1396-406.

11.

Palliative care, Version 1.2014. Featured updates to the NCCN Guidelines.

Levy MH, Smith T, Alvarez-Perez A, Back A, Baker JN, Block S, Codada SN, Dalal S, Dans M, Kutner JS, Kvale E, Misra S, Mitchell W, Sauer TM, Spiegel D, Sutton L, Taylor RM, Temel J, Tickoo R, Urba SG, Van Zyl C, Weinstein SM, Bergman MA, Scavone JL; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2014 Oct;12(10):1379-88.

PMID:
25313178
12.

Survivorship: healthy lifestyles, version 2.2014.

Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Dizon D, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Raza M, Rodriguez MA, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA; National comprehensive cancer network.

J Natl Compr Canc Netw. 2014 Sep;12(9):1222-37.

13.

Survivorship: immunizations and prevention of infections, version 2.2014.

Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Dizon D, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Raza M, Rodriguez MA, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA.

J Natl Compr Canc Netw. 2014 Aug;12(8):1098-111.

14.

Survivorship: cognitive function, version 1.2014.

Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Raza M, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2014 Jul;12(7):976-86.

15.

Survivorship: fatigue, version 1.2014.

Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Raza M, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian N, Freedman-Cass D.

J Natl Compr Canc Netw. 2014 Jun;12(6):876-87.

16.

NCCN guidelines for survivorship expanded to address two common conditions.

Kvale E, Urba SG.

J Natl Compr Canc Netw. 2014 May;12(5 Suppl):825-7.

PMID:
24853226
17.

Survivorship: sleep disorders, version 1.2014.

Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Raza M, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian N, Freedman-Cass D; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2014 May;12(5):630-42.

18.

Survivorship: pain version 1.2014.

Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Raza M, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian N, Freedman-Cass D; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2014 Apr;12(4):488-500.

19.

Survivorship: sexual dysfunction (male), version 1.2013.

Denlinger CS, Carlson RW, Are M, Baker KS, Davis E, Edge SB, Friedman DL, Goldman M, Jones L, King A, Kvale E, Langbaum TS, Ligibel JA, McCabe MS, McVary KT, Melisko M, Montoya JG, Mooney K, Morgan MA, O'Connor T, Paskett ED, Raza M, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian N, Freedman-Cass D; National comprehensive cancer network.

J Natl Compr Canc Netw. 2014 Mar 1;12(3):356-63.

20.

Survivorship: sexual dysfunction (female), version 1.2013.

Denlinger CS, Carlson RW, Are M, Baker KS, Davis E, Edge SB, Friedman DL, Goldman M, Jones L, King A, Kvale E, Langbaum TS, Ligibel JA, McCabe MS, McVary KT, Melisko M, Montoya JG, Mooney K, Morgan MA, O'Connor T, Paskett ED, Raza M, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian N, Freedman-Cass D; National compresensive cancer network.

J Natl Compr Canc Netw. 2014 Feb;12(2):184-92.

21.

Survivorship: introduction and definition. Clinical practice guidelines in oncology.

Denlinger CS, Carlson RW, Are M, Baker KS, Davis E, Edge SB, Friedman DL, Goldman M, Jones L, King A, Kvale E, Langbaum TS, Ligibel JA, McCabe MS, McVary KT, Melisko M, Montoya JG, Mooney K, Morgan MA, O'Connor T, Paskett ED, Raza M, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian N, Freedman-Cass D.

J Natl Compr Canc Netw. 2014 Jan;12(1):34-45.

22.

Efficacy of induction selection chemotherapy vs primary surgery for patients with advanced oral cavity carcinoma.

Chinn SB, Spector ME, Bellile EL, Rozek LS, Lin T, Teknos TN, Prince ME, Bradford CR, Urba SG, Carey TE, Eisbruch A, Wolf GT, Worden FP, Chepeha DB.

JAMA Otolaryngol Head Neck Surg. 2014 Feb;140(2):134-42. doi: 10.1001/jamaoto.2013.5892.

23.

Phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group study S0329.

Malhotra B, Moon J, Kucuk O, Clark JI, Urba SG, Wolf GT, Worden FP.

Head Neck. 2014 Dec;36(12):1712-7. doi: 10.1002/hed.23522. Epub 2014 Jan 29.

24.

Adult cancer pain.

Swarm RA, Abernethy AP, Anghelescu DL, Benedetti C, Buga S, Cleeland C, Deleon-Casasola OA, Eilers JG, Ferrell B, Green M, Janjan NA, Kamdar MM, Levy MH, Lynch M, McDowell RM, Moryl N, Nesbit SA, Paice JA, Rabow MW, Syrjala KL, Urba SG, Weinstein SM, Dwyer M, Kumar R; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2013 Aug;11(8):992-1022.

25.

Predictive factors in patients with advanced and metastatic squamous cell carcinoma of the head and neck: a study based on SWOG protocol S0420.

Mehta S, Moon J, Hashmi M, Leblanc M, Huang CH, Rinehart E, Wolf GT, Urba SG, Banerjee SK, Williamson S.

Oncol Rep. 2013 Jun;29(6):2095-100. doi: 10.3892/or.2013.2374. Epub 2013 Apr 2.

26.

Palliative care.

Levy MH, Adolph MD, Back A, Block S, Codada SN, Dalal S, Deshields TL, Dexter E, Dy SM, Knight SJ, Misra S, Ritchie CS, Sauer TM, Smith T, Spiegel D, Sutton L, Taylor RM, Temel J, Thomas J, Tickoo R, Urba SG, Von Roenn JH, Weems JL, Weinstein SM, Freedman-Cass DA, Bergman MA; NCCN (National Comprehensive Cancer Network).

J Natl Compr Canc Netw. 2012 Oct 1;10(10):1284-309.

PMID:
23054879
27.

Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer.

Schneider BJ, Lee JS, Hayman JA, Chang AC, Orringer MB, Pickens A, Pan CC, Merajver SD, Urba SG.

Invest New Drugs. 2013 Apr;31(2):435-42. doi: 10.1007/s10637-012-9864-0. Epub 2012 Jul 31.

28.

Antiemesis.

Ettinger DS, Armstrong DK, Barbour S, Berger MJ, Bierman PJ, Bradbury B, Ellis G, Kirkegaard S, Kloth DD, Kris MG, Lim D, Michaud LB, Nabati L, Noonan K, Rugo HS, Siler D, Sorscher SM, Stelts S, Stucky-Marshall L, Todaro B, Urba SG; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2012 Apr;10(4):456-85. No abstract available.

PMID:
22491046
29.

Clinical roundtable monograph. Treatment of chemotherapy-induced nausea and vomiting: a post-MASCC 2010 discussion.

Kris MG, Urba SG, Schwartzberg LS.

Clin Adv Hematol Oncol. 2011 Jan;9(1):suppl 1-15.

PMID:
21370520
30.

Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420.

Williamson SK, Moon J, Huang CH, Guaglianone PP, LeBlanc M, Wolf GT, Urba SG.

J Clin Oncol. 2010 Jul 10;28(20):3330-5. doi: 10.1200/JCO.2009.25.6834. Epub 2010 May 24.

31.

Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence.

Maxwell JH, Kumar B, Feng FY, Worden FP, Lee JS, Eisbruch A, Wolf GT, Prince ME, Moyer JS, Teknos TN, Chepeha DB, McHugh JB, Urba SG, Stoerker J, Walline HM, Kurnit DM, Cordell KG, Davis SJ, Ward PD, Bradford CR, Carey TE.

Clin Cancer Res. 2010 Feb 15;16(4):1226-35. doi: 10.1158/1078-0432.CCR-09-2350. Epub 2010 Feb 9.

32.

Chemotherapy alone for organ preservation in advanced laryngeal cancer.

Divi V, Worden FP, Prince ME, Eisbruch A, Lee JS, Bradford CR, Chepeha DB, Teknos TN, Hogikyan ND, Moyer JS, Tsien CI, Urba SG, Wolf GT.

Head Neck. 2010 Aug;32(8):1040-7. doi: 10.1002/hed.21285.

33.

Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618.

Arnold SM, Moon J, Williamson SK, Atkins JN, Ou SH, LeBlanc M, Urba SG.

Invest New Drugs. 2011 Apr;29(2):352-9. doi: 10.1007/s10637-009-9348-z. Epub 2009 Nov 25.

35.

Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion.

Worden FP, Moyer J, Lee JS, Taylor JM, Urba SG, Eisbruch A, Teknos TN, Chepeha DB, Prince ME, Hogikyan N, Lassig AA, Emerick K, Mukherji S, Hadjiski L, Tsien CI, Miller TH, Wallace NE, Mason HL, Bradford CR, Wolf GT.

Laryngoscope. 2009 Aug;119(8):1510-7. doi: 10.1002/lary.20294.

36.

Advanced squamous cell carcinoma of the oropharynx: efficacy of positron emission tomography and computed tomography for determining primary tumor response during induction chemotherapy.

Chepeha DB, Sacco AG, Oxford LE, Karamchandani R, Miller TH, Teknos TN, Bradford CR, Eisbruch A, Worden FM, Urba SG, Mukherji SK, Bui C, Frey KA, Wolf GT, Lee JS.

Head Neck. 2009 Apr;31(4):452-60. doi: 10.1002/hed.21006.

37.

Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number.

Worden FP, Kumar B, Lee JS, Wolf GT, Cordell KG, Taylor JM, Urba SG, Eisbruch A, Teknos TN, Chepeha DB, Prince ME, Tsien CI, D'Silva NJ, Yang K, Kurnit DM, Mason HL, Miller TH, Wallace NE, Bradford CR, Carey TE.

J Clin Oncol. 2008 Jul 1;26(19):3138-46. doi: 10.1200/JCO.2007.12.7597. Epub 2008 May 12.

38.

EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer.

Kumar B, Cordell KG, Lee JS, Worden FP, Prince ME, Tran HH, Wolf GT, Urba SG, Chepeha DB, Teknos TN, Eisbruch A, Tsien CI, Taylor JM, D'Silva NJ, Yang K, Kurnit DM, Bauer JA, Bradford CR, Carey TE.

J Clin Oncol. 2008 Jul 1;26(19):3128-37. doi: 10.1200/JCO.2007.12.7662. Epub 2008 May 12.

39.

Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking.

Kumar B, Cordell KG, Lee JS, Prince ME, Tran HH, Wolf GT, Urba SG, Worden FP, Chepeha DB, Teknos TN, Eisbruch A, Tsien CI, Taylor JM, D'Silva NJ, Yang K, Kurnit DM, Bradford CR, Carey TE.

Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S109-11.

40.

Targeting apoptosis to overcome cisplatin resistance: a translational study in head and neck cancer.

Bauer JA, Kumar B, Cordell KG, Prince ME, Tran HH, Wolf GT, Chepeha DB, Teknos TN, Wang S, Eisbruch A, Tsien CI, Urba SG, Worden FP, Lee J, Griffith KA, Taylor JM, D'Silva N, Wang SJ, Wolter KG, Henson B, Fisher SG, Carey TE, Bradford CR.

Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S106-8.

41.

Preoperative chemoradiation for the treatment of locoregional esophageal cancer: the standard of care?

Schneider BJ, Urba SG.

Semin Radiat Oncol. 2007 Jan;17(1):45-52.

PMID:
17185197
42.

Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.

Dragovich T, McCoy S, Fenoglio-Preiser CM, Wang J, Benedetti JK, Baker AF, Hackett CB, Urba SG, Zaner KS, Blanke CD, Abbruzzese JL.

J Clin Oncol. 2006 Oct 20;24(30):4922-7. Erratum in: J Clin Oncol. 2007 Jun 1;25(16):2334.

PMID:
17050876
43.

A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.

Worden FP, Moon J, Samlowski W, Clark JI, Dakhil SR, Williamson S, Urba SG, Ensley J, Hussain MH; Southwest Oncology Group, Head and Neck Working Group.

Cancer. 2006 Jul 15;107(2):319-27.

44.

Voice and swallowing outcomes of an organ-preservation trial for advanced laryngeal cancer.

Fung K, Lyden TH, Lee J, Urba SG, Worden F, Eisbruch A, Tsien C, Bradford CR, Chepeha DB, Hogikyan ND, Prince ME, Teknos TN, Wolf GT.

Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1395-9. Epub 2005 Aug 8.

PMID:
16087298
45.

Organ preservation for advanced resectable cancer of the base of tongue and hypopharynx: a Southwest Oncology Group Trial.

Urba SG, Moon J, Giri PG, Adelstein DJ, Hanna E, Yoo GH, Leblanc M, Ensley JF, Schuller DE.

J Clin Oncol. 2005 Jan 1;23(1):88-95.

PMID:
15625363
46.

Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study.

Urba SG, Chansky K, VanVeldhuizen PJ, Pluenneke RE, Benedetti JK, Macdonald JS, Abbruzzese JL; Southwest Oncology Group Study.

Invest New Drugs. 2004 Jan;22(1):91-7.

47.

Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma.

Urba SG, Orringer MB, Ianettonni M, Hayman JA, Satoru H.

Cancer. 2003 Nov 15;98(10):2177-83.

Supplemental Content

Loading ...
Support Center